Let’s start with a number: 0.21%.
That’s the ownership stake Jiuan Medical, a $200M medical device manufacturer, purchased in DeepSeek for $100M. Let that sink in. They bought a seat at the table with no voting rights, no board seat, and no ability to influence the technology roadmap. This isn't a partnership. It’s a lottery ticket disguised as a press release.
Over the past five days, Jiuan’s stock surged on the news. Then it corrected. The market is already pricing in the reality: this is a financial trade, not a strategic acquisition. As a Battle Trader who has audited smart contracts since the DAO fork, I’ve seen this pattern before — it’s the same mechanism that pumps Dogecoin on a Musk tweet.
Context
Jiuan Medical, flush with cash from pandemic-era antigen test sales, announced investments of ~$100M (¥750M) into DeepSeek, $30M into Moonshot AI (Kimi), and ~$14M (¥100M) into Baichuan Intelligence (LeapStar). These are three of China’s most hyped large language model startups. The holdings are purely passive. No operational control. No data sharing. No joint development. Just capital parked in unlisted equity.
Why should a crypto audience care? Because this is exactly what many crypto treasuries do during a bull run. They take profits from DeFi yields and dump them into VC deals — small checks into hot narratives, hoping for a second-order pump. The difference? In crypto, we have on-chain transparency. In traditional markets, you get a press release and a 0.21% token.
Core: The Incentive Misalignment Cascade
Let me break this down using the same framework I use to audit DAO treasuries.
1. The Valuation Trap DeepSeek’s implied valuation from Jiuan’s $100M for 0.21% is ~$47.6B. That’s roughly 10x the entire market cap of Arbitrum. DeepSeek’s revenue? Let’s be generous and say $50M. That’s a 952x price-to-sales multiple. In crypto, we call that an overvalued L1 token pre-TGE. The problem is that Jiuan’s investment is illiquid — it cannot be traded on a DEX.
2. The Passive Dilution Risk Jiuan holds 0.21% of a company that will likely raise multiple more rounds before any liquidity event. Each round dilutes them. Without pro-rata rights (which are not mentioned), Jiuan could end up with 0.05% by Series D. In crypto, we see this with early-stage SAFT investors who get eaten by later rounds with higher valuations and lower discounts.
3. The Exit Illusion Jiuan’s path to cash? IPO or acquisition. But the Chinese IPO market for unprofitable AI companies is shaky. And who acquires a $47B company at a 0.21% stake? No one buys you out at that level. You’re a rounding error. This is worse than holding a governance token in a DAO with no proposal power.
4. The Portfolio Diversification Mirage Jiuan invested in three different AI companies: DeepSeek (architecture innovation), Kimi (long-context application), Baichuan (general model). This looks like a balanced portfolio. But in reality, all three face the exact same systemic risk: GPU supply shortages, regulatory crackdown, and a potential AI winter. It’s like buying ETH, SOL, and AVAX and calling it diversified — all correlate to the same macro beta.
Contrarian: What Smart Money Is Actually Doing
The mainstream narrative says Jiuan is “betting on the future of AI.” The contrarian take is that Jiuan is signaling desperation to its shareholders. The pandemic cash is burning a hole in their balance sheet. The core medical business is declining. So they buy a story.
In crypto, we see the same behavior: protocols that generate surplus treasury — like Uniswap’s $4B or Arbitrum’s $3B — often make low-conviction investments in other protocols to show “ecosystem growth.” In reality, it’s lazy capital deployment. I’ve audited DAO treasuries that allocated 10% to random NFT projects because the multisig signers wanted to ride the hype. The result? Underperformance and community backlash.
What should they have done? Buy back their own token. Or deploy liquidity into their own pools. Or, if they must invest, take a governance seat and demand concrete revenue-sharing agreements. Passive capital in a hot sector is not an investment; it’s a regress to the mean.
Takeaway
Jiuan’s move is a classic retail trap dressed in institutional clothing. The market will eventually price this correctly. For crypto capital allocators, the lesson is brutal: if you can’t audit the code, own the governance, or at least control the LP tokens, then your 0.21% is just a vanity metric.
The real alpha isn’t in buying a piece of the narrative. It’s in identifying when the narrative becomes a trap. And right now, the trap is set.
— Root: Auditing the DAO and Ethereum
We farmed the yields until the protocol farmed us.
— Root: Auditing the DAO and Ethereum
